close

Fundraisings and IPOs

Date: 2011-09-05

Type of information: Grant

Company: Telormedix (Switzerland)

Investors: European Eurostars Programme (EU)

Amount: € 729,500

Funding type: grant

Planned used:

The grant will fund the two-year research project LIPODEL. The project’s main focus will be to enhance technologies in order to improve immune responses for preventive and curative purposes. Telormedix will coordinate three research teams to develop liposomes targeting monocytes and plasmacytoid pre-dendritic cells co-delivering TLR7 agonists for immunotherapy. LIPODEL liposomes will then be used to assemble a Group B Streptococcus vaccine candidate. The three additional research teams participating in the LIPODEL project are: Minervax ApS (Denmark); Technical University of Denmark (Denmark); and Bioneer A/S (Denmark).

Others:

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases,has raised funding from the European Eurostars Programme to coordinate a two-year research project aimed at developing liposomes for vaccine and adjuvant delivery. The project, operating under the acronym LIPODEL, will have a total budget of € 729,500.

Therapeutic area: Cancer - Oncology - Inflammatory diseases

Is general: Yes